Skip to content
stoqly

Myriad Genetics Inc

MYGN Nasdaq In Vitro & In Vivo Diagnostic Substances Financials FY2015–FY2025

Revenue Total sales reported in the income statement.
$825M
1.6% vs prior year
Operating margin Operating income as a share of revenue.
−47.0%
32.2 pts
Net income Profit after all expenses, interest and tax.
−$366M
Free cash flow Cash from operations minus capital spending.
—
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−90.4%
75.1 pts
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$1.20 EPS (TTM)

What Myriad Genetics Inc does

No business description yet.

Legal name
MYRIAD GENETICS INC
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 24, 2026
Accession · CIK
0000899923-26-000018
0000899923

Revenue and margins

Myriad Genetics Inc had $825M of revenue in fiscal 2025, down 1.6% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Myriad Genetics Inc returned — to shareholders in fiscal 2025. The diluted share count rose 2.2%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Myriad Genetics Inc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $339M$115M$141M$102M$150M
Debt incl. finance leases $0.0M$0.0M$38.5M$39.6M$120M
Debt / equity 0.0x0.0x0.0x0.1x0.3x
Interest coverage −28.9x−43.9x−88.8x−44.1x−36.9x
Current ratio 2.4x2.0x2.0x1.8x2.5x
Quick ratio 2.3x1.9x1.9x1.6x2.3x
Total assets $1.3B$1.2B$1.1B$1.0B$707M
Total liabilities $353M$313M$363M$327M$339M
Shareholders' equity $968M$886M$783M$701M$368M
Net debt (− = net cash) −$339M−$115M−$102M−$62.8M−$29.7M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY15FY16FY17FY18FY20FY21FY22FY23FY24FY25
Net income is positive ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕
Cash from operations is positive ✓ ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✓
Return on assets rose — ✕ ✓ ✕ — ✓ ✕ ✕ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✕ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — ✓ ✕ — ✓ ✕ ✕ ✕ ✕
Current ratio rose — ✕ ✓ ✕ — ✕ ✕ ✓ ✕ ✓
Share count didn't rise — ✓ ✕ ✕ — ✕ ✕ ✕ ✕ ✕
Gross margin rose — ✕ — — — — — ✕ ✓ ✓
Revenue rose relative to assets — ✕ ✕ ✕ — ✓ ✓ ✓ ✓ ✓
F-score — / 34 / 85 / 83 / 8— / 35 / 82 / 83 / 94 / 95 / 9
Accruals ratio −5.6%−8.5%1.5%−5.8%−18.3%−3.3%−0.5%−13.0%−10.9%−42.4%
Altman Z'' 8.572.326.953.471.232.681.94−0.13−0.10−5.88

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY15FY16FY17FY18FY20FY21FY22FY23FY24FY25
Income statement
Revenue $754M $771M $744M $851M $639M $691M $678M $753M $838M $825M
Gross profit $621M $626M — — — — $476M $517M $585M $577M
Research and development $70.6M $74.4M $70.8M $85.9M $77.2M $81.9M $85.4M $88.7M $113M $107M
Operating income $153M $44.0M $122M $7.6M −$232M −$191M −$141M −$257M −$124M −$387M
Interest expense $0.3M $6.0M $3.2M $12.0M $10.8M $6.6M $3.2M $2.9M $2.8M $10.5M
Pretax income $156M $36.2M $120M $0.0M −$223M −$57.1M −$141M −$262M −$124M −$395M
Income tax $38.8M $19.0M −$13.0M −$4.4M −$23.7M −$29.9M −$28.6M $1.1M $3.8M −$29.2M
Net income $117M $17.4M $133M $4.6M −$200M −$27.2M −$112M −$263M −$127M −$366M
Diluted EPS $1.60 $0.25 $1.85 $0.06 −$2.69 −$0.35 −$1.39 −$3.18 −$1.41 −$3.95
Diluted shares 0.07B 0.07B 0.07B 0.08B 0.07B 0.08B 0.08B 0.08B 0.09B 0.09B
Cash flow
Cash from operations $166M $106M $116M $83.7M $60.7M $18.6M −$106M −$111M −$8.7M $1.8M
Capital expenditure $5.0M $6.1M $8.4M $8.6M $10.2M $18.0M $45.3M — — —
Free cash flow $161M $100M $108M $75.1M $50.5M $0.6M −$152M — — —
Depreciation and amortization $26.8M $48.3M $54.4M $73.0M $72.0M $62.8M $52.7M $61.9M $61.2M $53.7M
Stock-based compensation $31.6M $29.9M $27.1M $33.5M $25.2M $36.3M $38.1M $40.7M $49.8M $35.2M
Acquisitions $37.0M $216M $0.0M $279M $0.0M $0.0M $57.2M $0.0M $0.0M —
Share buybacks $163M $31.6M $0.0M $50.0M $0.0M $0.0M — — — —
Dividends and buybacks $163M $31.6M $0.0M $50.0M $0.0M $0.0M — — — —
Balance sheet
Cash and short-term investments $159M $151M $181M $137M $151M $339M $115M $141M $102M $150M
Total debt — $99.1M $9.3M $234M $225M $0.0M $0.0M $38.5M $39.6M $120M
Current assets $315M $302M $328M $349M $389M $485M $275M $314M $298M $333M
Current liabilities $72.3M $218M $102M $118M $146M $204M $137M $156M $164M $134M
Inventory $38.3M $42.2M $34.3M $31.4M $27.1M $15.3M $20.1M $22.0M $27.5M $30.6M
Property and equipment, net $58.3M $51.1M $43.2M $57.3M $40.7M $43.5M $83.4M $119M $117M $114M
Goodwill $195M $316M $319M $417M $329M $239M $287M $287M $286M $51.6M
Intangible assets $228M $492M $455M $685M $577M $404M $380M $350M $262M $153M
Total assets $881M $1.2B $1.2B $1.6B $1.4B $1.3B $1.2B $1.1B $1.0B $707M
Total liabilities $132M $441M $209M $474M $538M $353M $313M $363M $327M $339M
Shareholders' equity $740M $768M $966M $1.1B $881M $968M $886M $783M $701M $368M
Margins
Gross margin 82.4% 81.2% — — — — 70.2% 68.6% 69.9% 69.9%
Operating margin 20.4% 5.7% 16.4% 0.9% −36.3% −27.6% −20.7% −34.2% −14.7% −47.0%
EBITDA margin 23.9% 12.0% 23.7% 9.5% −25.0% −18.5% −13.0% −26.0% −7.4% −40.4%
Net margin 15.5% 2.3% 17.9% 0.5% −31.2% −3.9% −16.5% −35.0% −15.2% −44.4%
FCF margin 21.4% 13.0% 14.5% 8.8% 7.9% 0.1% −22.3% — — —
Returns
Return on capital — 4.0% 15.3% 0.5% −19.2% −23.9% −14.4% −29.9% −15.3% −90.4%
Return on capital employed 19.0% 4.4% 11.4% 0.5% −18.2% −17.1% −13.2% −26.0% −14.3% −67.6%
Return on equity 15.8% 2.3% 15.4% 0.4% −22.6% −2.9% −12.1% −31.6% −17.2% −68.5%
Return on assets 13.3% 1.7% 11.2% 0.3% −14.1% −2.0% −8.9% −22.5% −11.7% −42.2%
Return on tangible equity 37.0% — 69.3% — — −8.4% −51.1% −180.0% −83.5% −224.5%
Growth
Revenue growth — 2.3% −3.6% 14.4% — 8.1% −1.8% 11.0% 11.2% −1.6%
Net income growth — −85.2% 666.1% −96.5% — — — — — —
EPS growth — −84.4% 640.0% −96.8% — — — — — —
FCF growth — −37.9% 7.4% −30.1% — −98.8% −25,366.7% — — —
Share count change — −6.3% 4.7% 5.6% — 5.0% 3.3% 2.7% 9.4% 2.2%
Financial health
Net debt / EBITDA — −0.6x −1.0x 1.2x — — — — — —
Debt / equity — 0.1x 0.0x 0.2x 0.3x 0.0x 0.0x 0.0x 0.1x 0.3x
Interest coverage 511.3x 7.3x 38.1x 0.6x −21.5x −28.9x −43.9x −88.8x −44.1x −36.9x
Current ratio 4.3x 1.4x 3.2x 3.0x 2.7x 2.4x 2.0x 2.0x 1.8x 2.5x
Quick ratio 3.8x 1.2x 2.9x 2.7x 2.5x 2.3x 1.9x 1.9x 1.6x 2.3x
Capital allocation
Capex / revenue 0.7% 0.8% 1.1% 1.0% 1.6% 2.6% 6.7% — — —
Stock comp / revenue 4.2% 3.9% 3.6% 3.9% 3.9% 5.3% 5.6% 5.4% 5.9% 4.3%
Payouts / FCF 100.8% 31.6% 0.0% 66.6% 0.0% 0.0% — — — —
Quality scores
Piotroski F-score — 4.0 5.0 3.0 — 5.0 2.0 3.0 4.0 5.0
Altman Z'' 8.6 2.3 7.0 3.5 1.2 2.7 1.9 −0.1 −0.1 −5.9
Accruals ratio −5.6% −8.5% 1.5% −5.8% −18.3% −3.3% −0.5% −13.0% −10.9% −42.4%

Source: SEC EDGAR XBRL filings (CIK 0000899923). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open